# Applicant:

Quidel Corporation 10165 McKellar Court San Diego, California 92121 Telephone: 858-552-7910 Fax: 858-646-8045

# Contact Information:

Ronald H. Lollar, Senior Director Clinical and Quality Affairs   
1055 East State Street   
Suite 100   
Athens, Ohio 45701   
740-589-3300 - Corporate number   
740-589-3373 - Desk phone   
740-593-8437 - Fax   
lollar@dhiusa.com

# Date of preparation of 510(k) summary:

November 30, 2011

# Device Name:

Trade name - Quidel Molecular hMPV Assay   
Classification name  Respiratory viral panel multiplex nucleic acid assay   
Product Code - OEM   
Regulation - 21 CFR 866.3980

Legally marketed devices to which equivalence is claimed:

# Gen-Probe Prodesse Pro hMPV $^ +$ (k082688)

The Pro hMPV+ Assay is a Real Time RT-PCR in vitro diagnostic test for the qualitative detection of human Metapneumovirus (hMPV) nucleic acid isolated and purified from nasopharyngeal swab (NP) specimens obtained from individuals exhibiting signs and symptoms of acute respiratory infection. This assay targets a highly conserved region of the Nucleocapsid gene of hMPV. The detection of hMPV nucleic acid from symptomatic patients aids in the diagnosis of human respiratory hMPV infection if used in conjunction with other clinical and laboratory findings. This test is not intended to differentiate the four genetic sub-lineages of hMPV.

Negative results do not preclude hMPV infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.

# Intended Use:

The Quidel Molecular hMPV_assay is a multiplex Real Time RT-PCR assay for the in vitro qualitative detection of human metapneumovirus RNA in nasal and nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection. This test is intended for use as an aid in the differential diagnosis of human metapneumovirus infections in humans in conjunction with clinical and epidemiological risk factors. This test is not intended to differentiate the four genetic sub-lineages of hMPV.

Negative results do not preclude hMPV infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

# Device Description:

The Quidel Molecular hMPV Assay detects viral nucleic acids that have been extracted from a patient sample using the NucliSENS $\textsuperscript { \textregistered }$ easyMAG $\textsuperscript { \textregistered }$ automated extraction platform. A multiplex RT-PCR reaction is carried out under optimized conditions in a single tube generating amplicons for each of the target viruses present in the sample. This reaction is performed utilizing the Applied Biosystems® 7500 Fast Dx platform. Identification of hMPV occurs by the use of target specific primers and a fluorescent- labeled probe that hybridizes to conserved regions in the RNA dependent RNA polymerase gene of hMPV.

The following is a summary of the procedure:

1. Sample Collection: Obtain nasal or nasopharyngeal swab specimens using standard techniques from symptomatic patients. These specimens are transported, stored, and processed according to established laboratory procedures.

2. Nucleic Acid Extraction: Extract Nucleic Acids from the specimens with the NucliSENS easyMAG System following the manufacturer's instructions using the appropriate reagents.

Prior to the extraction procedure add $2 0 ~ \mu \mathrm { L }$ of the Process Control (PRC) to each $1 8 0 ~ \mu \mathrm { L }$ aliquot of specimen. The PRC serves to monitor inhibitors in the extracted specimen, assures that adequate amplification has taken place and that nucleic acid extraction was sufficient.

3. Rehydration of Master Mix: Rehydrate the lyophilized Master Mix using $1 3 5 \mu \mathrm { L }$ of Rehydration Solution. The Master. Mix contains oligonucleotide primers, fluorophore and quencher-labeled probes targeting highly conserved regions of hMPV as well as the process control sequence. The primers are complementary to highly specific and conserved regions in the genome of the virus. The probes are dual labeled with a reporter dye attached to the 5'end and a quencher attached to the $_ { 3 } ,$ end. The rehydrated Master Mix is sufficient for eight reactions.

4. Nucleic Acid Amplification and Detection: Add $1 5 ~ \mu \mathrm { L }$ of the rehydrated Master Mix to each reaction plate well. $5 \mu \mathrm { L }$ of extracted nucleic acids (specimen with PRC) is then added to the plate well. Then place the plate into the Applied Biosystems 7500 FastDx.

Once the plate is added to the instrument, the assay protocol is initiated. This protocol initiates reverse transcription of the RNA targets generating complementary DNA, and the subsequent amplification of the target amplicons occurs. The Quidel Molecular hMPV assay is based on TaqMan $\textsuperscript { \textregistered }$ chemistry, and uses an enzyme with reverse transcriptase, DNA polymerase, and $5 ^ { \circ } { - } 3 ^ { \circ }$ exonuclease activities. During DNA amplification, this enzyme cleaves the probe bound to the complementary DNA sequence, separating the quencher dye from the reporter dye. This step generates an increase in fluorescent signal upon excitation by a light source of the appropriate wavelength. With each cycle, additional dye molecules are separated from their quenchers resulting in additional signal. If sufficient fluorescence is achieved by 35 cycles during the data collection stage of amplification, the sample is reported as positive for the detected nucleic acid.

# Device Comparison

The Quidel Molecular hMPV assay was compared to legally marketed RTPCR assay. The characteristics of Quidel Molecular hMPV assay ("Subject Device") and the Prodesse Pro hMPV $\ F$ ("Predicate Device") are described in Table 5.1, below:

<table><tr><td colspan="3" rowspan="1">Table 5.1:   Subject Device and Comparator Device Comparison</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Subject DeviceQuidel Molecular hMPV Assay</td><td colspan="1" rowspan="1">Predicate DeviceProdesse ProFlu+</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="2" rowspan="1">The Quidel Molecular hMPV         The Pro hMPV+ Assay is a Realassay is a multiplex Real Time       Time RT-PCR in vitro diagnosticRT-PCR assay for the in vitro       test for the qualitative detection ofqualitative detection of human       human Metapneumovirus (hMPV)metapneumovirus RNA in nasal     nucleic acid isolated and purifiedand nasopharyngeal swab             from nasopharyngeal swab (NP)specimens from patients with         specimens obtained fromsigns and symptoms of respiratory  individuals exhibiting signs andinfection. This test is intended for   symptoms of acute respiratoryuse as an aid in the differential       infection. This assay targets adiagnosis of human                      highly conserved region of themetapneumovirus infections in      Nucleocapsid gene of hMPV. Thehumans in conjunction with          detection of hMPV nucleic acidclinical and epidemiological risk    from symptomatic patients aids infactors. This test is not intended to  the diagnosis of human respiratorydifferentiate the four genetic sub-   hMPV infection if used inlineages of hMPV.                      conjunction with other clinical andlaboratory findings. This test is notNegative results do not preclude     intended to differentiate the fourhMPV infection and should not be genetic sub-lineages of hMPV.used as the sole basis for               Negative results do not precludediagnosis, treatment or other         hMPV infection and should not bepatient management decisions.      used as the sole basis for diagnosis,treatment or other managementdecisions.</td></tr><tr><td colspan="1" rowspan="1">Assay Target</td><td colspan="1" rowspan="1">hMPV</td><td colspan="1" rowspan="1">hMPV</td></tr><tr><td colspan="1" rowspan="1">SampleTypes</td><td colspan="1" rowspan="1">nasal and nasopharyngeal swabspecimens</td><td colspan="1" rowspan="1">nasopharyngeal swab</td></tr><tr><td colspan="1" rowspan="1">ExtractionMethods</td><td colspan="1" rowspan="1">bioMérieux easyMAG AutomatedMagnetic Extraction Reagents</td><td colspan="1" rowspan="1">Roche MagNA Pure LC Total NucleicAcid Isolation Kit or the bioMérieuxeasyMAG Automated MagneticExtraction Reagents</td></tr><tr><td colspan="1" rowspan="1">AssayMethodology</td><td colspan="1" rowspan="1">PCR-based system for detecting thepresence or absence of viral RNA inclinical specimens</td><td colspan="1" rowspan="1">PCR-based system for detecting thepresence or absence of viral RNA inclinical specimens</td></tr><tr><td colspan="1" rowspan="1">DetectionTechniques</td><td colspan="1" rowspan="1">Multiplex assay using differentreporter dyes for each target</td><td colspan="1" rowspan="1">Multiplex assay using differentreporter dyes for each target</td></tr><tr><td colspan="3" rowspan="1">Table 5.1:    Subject Device and Comparator Device Comparison</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Subject DeviceQuidel Molecular hMPV Assay</td><td colspan="1" rowspan="1">Predicate DeviceProdesse ProFlu+</td></tr><tr><td colspan="1" rowspan="1">Viral Targets</td><td colspan="1" rowspan="1">RNA polymerase gene</td><td colspan="1" rowspan="1">Nucleocapsid</td></tr><tr><td colspan="1" rowspan="1">LoD</td><td colspan="1" rowspan="1">The analytical sensitivity (limit ofdetection or LoD) of the QuidelMolecular hMPV assay wasdetermined using quantified(TCID5o/mL) cultures of 4 hMPVstrains (A1, A2, B1, B2) seriallydiluted in negativenasopharyngeal matrix. Eachdilution was extracted using theNucliSENS easyMAG Systemand tested in replicates of 20 perconcentration of virus on both theApplied Biosystems® 7500 FastDx platform. Analyticalsensitivity (LoD) is defined as thelowest concentration at which95% of all replicates testedpositive, ranged from 10' to 10°TCID50/mL.</td><td colspan="1" rowspan="1">The analytical sensitivity (limit ofdetection or LoD) of the ProhMPV+ Assay was determinedusing quantified (TCID50/mL)cultures of 2 hMPV (subtype A2and subtype B2) strains seriallydiluted in nasopharyngeal clinicalmatrix. Each viral strain wasextracted using the Roche MagNAPure LC instrument and tested inreplicates of 20 per concentrationof virus.Analytical sensitivity (LoD) asdefined as the lowest concentrationat which ≥ 95% of all replicatestested positive, ranged from 10² -10' TCID50/mL.</td></tr></table>

# Analytical Performance:

# Reproducibility:

The reproducibility of the Quidel Molecular hMPV assay was evaluated at 3 laboratory sites. Reproducibility was assessed using a panel of 4 simulated samples that included a medium positive hMPV sample ( $2 . 6 5 \mathrm { E } { + 0 2 }$ EY $\mathrm { T C I D } _ { 5 0 } / \mathrm { m L } )$ a low positive hMPV sample $( 1 . 0 6 \mathrm { E } + 0 2 \ \mathrm { T C I D } _ { 5 0 } / \mathrm { m L } )$ , a high negative hMPV sample $\mathrm { 1 . 5 9 E + 0 1 \ T C I D _ { 5 0 } / m L ) }$ and a negative. Panels and controls were tested at each site by 2 operators for 5 days in triplicate (2 operators X 5 days X triplicate testing X 3 sites $= 9 0$ results per sample). The panels and controls were extracted using the bioMérieux easyMAG system and tested on the ABI 7500Fast Dx.

<table><tr><td rowspan=1 colspan=11>Table 5.2: Reproducibility</td></tr><tr><td rowspan=2 colspan=1>PanelMember ID</td><td rowspan=1 colspan=3>Site 1</td><td rowspan=1 colspan=3>Site 2</td><td rowspan=1 colspan=3>Site 3</td><td rowspan=2 colspan=1>TotalResults</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>AVECt</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>AVECt</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>AVECt</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>hMPV HighNegative(1.59E+01TCIDs/mL)</td><td rowspan=1 colspan=1>10/30</td><td rowspan=1 colspan=1>33.36*</td><td rowspan=1 colspan=1>5.08</td><td rowspan=1 colspan=1>10/30</td><td rowspan=1 colspan=1>32.76*</td><td rowspan=1 colspan=1>3.38</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>20/90</td></tr><tr><td rowspan=1 colspan=1>hMPV LowPositive(1.06E+02TCIDs/mL)</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>28.73</td><td rowspan=1 colspan=1>5.28</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>28.18</td><td rowspan=1 colspan=1>8.42</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>30.18</td><td rowspan=1 colspan=1>4.89</td><td rowspan=1 colspan=1>89/90</td></tr><tr><td rowspan=1 colspan=1>hMPV MediumPositive.(2.65E+02TCIDs/mL)</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>25.09</td><td rowspan=1 colspan=1>6.65</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>25.18</td><td rowspan=1 colspan=1>7.63</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>26.58</td><td rowspan=1 colspan=1>5.68</td><td rowspan=1 colspan=1>90/90</td></tr><tr><td rowspan=1 colspan=1>Negative Sample</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0/30</td></tr><tr><td rowspan=1 colspan=1>hMPV PositiveControl</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>18.37</td><td rowspan=1 colspan=1>3.88</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>18.48</td><td rowspan=1 colspan=1>4.35</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>18.60</td><td rowspan=1 colspan=1>3.08</td><td rowspan=1 colspan=1>90/90</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0/30</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0/30</td></tr></table>

\* CV of positive results

The data from the combined sites indicates that the Quidel Molecular hMPV assay generates reproducible results for hMPV when tested with the ABI 7500 Fast Dx.

# Limit of Detection

The analytical sensitivity (limit of detection or LoD) of the Quidel Molecular hMPV assay was determined using quantified $\mathrm { ( T C I D _ { 5 0 } / m L ) }$ cultures of 4 hMPV strains (A1, A2, B1, B2) serially diluted in negative nasopharyngeal matrix. Each dilution was extracted using the NucliSENS easyMAG System and tested in replicates of 20 per concentration of virus on both the Applied Biosystems $\textsuperscript { \textregistered }$ 7500 Fast $\mathbf { D x }$ platform. Analytical sensitivity (LoD) is defined as the lowest concentration at which $9 5 \%$ of all replicates tested positive.

<table><tr><td rowspan=1 colspan=2>Table 5.3: Level of Detection</td></tr><tr><td rowspan=2 colspan=1>Strain</td><td rowspan=1 colspan=1>FinalTCID50/mL LoD</td></tr><tr><td rowspan=1 colspan=1>7500 Fast Dx</td></tr><tr><td rowspan=1 colspan=1>hMPV A1</td><td rowspan=1 colspan=1>5.29E+01</td></tr><tr><td rowspan=1 colspan=1>hMPV A2</td><td rowspan=1 colspan=1>1.39E+01</td></tr><tr><td rowspan=1 colspan=1>hMPV B1</td><td rowspan=1 colspan=1>3.15E+00</td></tr><tr><td rowspan=1 colspan=1>hMPV B2</td><td rowspan=1 colspan=1>1.07E+01</td></tr></table>

# Analytical reactivity (inclusivity)

The reactivity of the Quidel Molecular hMPV assay was evaluated against multiple strains of hMPV. The clinical panel consisted of 12 hMPV strains (3 A1, 2 A-2, 3 B-1, and 4 B-2). Each panel member was extracted using the NucliSens easyMAG instrument and tested in triplicate.

The Quidel Molecular hMPV assay detected $100 \%$ of the hMPV at $1 0 ^ { 0 }$ to $1 0 ^ { 2 }$ EY $\mathrm { T C I D } _ { 5 0 / \mathrm { m L } }$ levels on both the Applied Biosystems $\textsuperscript { \textregistered }$ 7500 Fast Dx platform.

<table><tr><td rowspan=1 colspan=4>Table 5.4: hMPV Inclusivity Panel</td></tr><tr><td rowspan=1 colspan=1>Subtype</td><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>TCID50/mL</td><td rowspan=1 colspan=1>(7500 Dx)</td></tr><tr><td rowspan=1 colspan=1>AI</td><td rowspan=1 colspan=1>Italy</td><td rowspan=1 colspan=1>1.11E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>B1</td><td rowspan=1 colspan=1>Italy</td><td rowspan=1 colspan=1>2.20E+0</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>B2</td><td rowspan=1 colspan=1>Italy</td><td rowspan=1 colspan=1>4.50E+1</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>BI</td><td rowspan=1 colspan=1>Peru2-2002 G Gene</td><td rowspan=1 colspan=1>4.17E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>B2</td><td rowspan=1 colspan=1>Perul-2002 G Gene</td><td rowspan=1 colspan=1>1.26E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>B1</td><td rowspan=1 colspan=1>Peru3-2003 G Gene</td><td rowspan=1 colspan=1>1.26E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>B2</td><td rowspan=1 colspan=1>Peru6-2003</td><td rowspan=1 colspan=1>5.01E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>A1</td><td rowspan=1 colspan=1>IA3-2002 G Gene</td><td rowspan=1 colspan=1>1.51E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>A1</td><td rowspan=1 colspan=1>IA10-2003</td><td rowspan=1 colspan=1>3.80E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>B2</td><td rowspan=1 colspan=1>IA18-2003 G Gene</td><td rowspan=1 colspan=1>6.61E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>A2</td><td rowspan=1 colspan=1>IA14-2003 G Gene</td><td rowspan=1 colspan=1>1.95E+2</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>A2</td><td rowspan=1 colspan=1>Clinical Isolate</td><td rowspan=1 colspan=1>1.05E+2</td><td rowspan=1 colspan=1>Positive</td></tr></table>

# Analytical specificity (cross-reactivity)

The analytical specificity of the Quidel Molecular hMPV assay was evaluated by testing a panel consisting of 26 viral, 24 bacterial, and 1 yeast strain representing common respiratory pathogens or flora commonly_ present in nasopharynx. Bacteria and yeast were tested at concentrations of $1 \dot { 0 } ^ { 5 }$ to $\mathbf { \mathbb { i } } 0 ^ { \mathbf { \downarrow 0 } } \mathbf { C F U / m L }$ : Viruses were tested at concentrations of $1 0 ^ { 3 }$ to $1 0 ^ { 8 } ~ \mathrm { T C I D } _ { 5 0 } / \mathrm { m L }$ . Samples were extracted using the NucliSENS easyMAG instrument and tested in triplicate. Analytical specificity of the Quidel Molecular hMPV assay was $100 \%$ .

<table><tr><td colspan="3">Table 5.5: Cross-reactivity</td></tr><tr><td>Organism ID</td><td>TCID50/mL or CFU/mL</td><td>hMPV Result</td></tr><tr><td colspan="1" rowspan="1">Organism ID</td><td colspan="1" rowspan="1">TCID50/mLor CFU/mL</td><td colspan="1" rowspan="1">hMPVResult</td></tr><tr><td colspan="1" rowspan="1">RSV Long</td><td colspan="1" rowspan="1">4.40E+04</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">RSV Washington</td><td colspan="1" rowspan="1">1.75E+04</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">A/Mexico/4108/2009</td><td colspan="1" rowspan="1">1.40E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">B/Florida/04/2006</td><td colspan="1" rowspan="1">5.25E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 1/Adenoid 71</td><td colspan="1" rowspan="1">5.67E+04</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Coronavirus 229E</td><td colspan="1" rowspan="1">1.70E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Coronavirus OC43</td><td colspan="1" rowspan="1">1.67E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B4</td><td colspan="1" rowspan="1">2.43E÷06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B5/10/2006</td><td colspan="1" rowspan="1">2.28E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">8.76E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Echovirus 7</td><td colspan="1" rowspan="1">5.38E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Echovirus 9</td><td colspan="1" rowspan="1">1.50E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Echovirus 6</td><td colspan="1" rowspan="1">1.05E÷08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Echovirus 11</td><td colspan="1" rowspan="1">1.50E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 71</td><td colspan="1" rowspan="1">2.68E+03</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 70</td><td colspan="1" rowspan="1">1.66E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Epstein Barr Virus</td><td colspan="1" rowspan="1">5,000cp/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">HSV Type 1 Maclnytre strain</td><td colspan="1" rowspan="1">1.95E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">HSV Type 2 G strain</td><td colspan="1" rowspan="1">3.67E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Rubeola</td><td colspan="1" rowspan="1">3.78E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mumps virus</td><td colspan="1" rowspan="1">8.43E+04</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza Type 1</td><td colspan="1" rowspan="1">2.50E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza Type 2</td><td colspan="1" rowspan="1">2.20E+04</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza Type 3</td><td colspan="1" rowspan="1">9.10E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza Type 4</td><td colspan="1" rowspan="1">9.57E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Varicella Zoster Virus</td><td colspan="1" rowspan="1">7.50E+02</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">1.04E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Bordetella bronchiseptica</td><td colspan="1" rowspan="1">2.55E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Chlamydia trachomatis</td><td colspan="1" rowspan="1">2.10E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">2.05E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycobacterium intracellulare</td><td colspan="1" rowspan="1">6.90E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycobacterium tuberculosis</td><td colspan="1" rowspan="1">6.60E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycobacterium avium</td><td colspan="1" rowspan="1">1.36E+10</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae</td><td colspan="1" rowspan="1">5.90E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">5.15E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Proteus vulgaris    •</td><td colspan="1" rowspan="1">2.65E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">2.75E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria gonorrhoeae</td><td colspan="1" rowspan="1">2.15E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria menigitidis</td><td colspan="1" rowspan="1">1.85E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria mucosa</td><td colspan="1" rowspan="1">1.85E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">3.30E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">6.80E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Moraxella catarrhalis</td><td colspan="1" rowspan="1">5.85E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium diptheriae</td><td colspan="1" rowspan="1">6.0E+05</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus plantarum</td><td colspan="1" rowspan="1">1.03E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">4.5E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1">2.05E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus salivarius</td><td colspan="1" rowspan="1">2.50E+06</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">2.6E+07</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">5.15E+08</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">1.07E+06</td><td colspan="1" rowspan="1">Negative</td></tr></table>

# Clinical Performance:

Performance characteristics of the Quidel Molecular hMPV assay were established during a prospective study during the 2010-2011 respiratory virus season (January to March 2011). A total of 1116 specimens were evaluated in this study (742-fresh, 374- frozen). Of the fresh specimens, 399 specimens were nasal swabs, and 343 were nasopharyngeal swabs. The fresh specimens were collected for routine respiratory virus testing at thirteen sites across the United States. The frozen specimens were collected and tested at two geographically distinct locations and were comprised of 374 nasopharyngeal swabs.

The 11 16 specimens were tested by both the subject and a comparator device for human metapneumovirus RNA. Sixteen of these specimens were invalid on initial testing with the subject device $( 1 . 4 \% )$ . Re-testing of the specimens according to the Interpretation algorithm described above also yielded invalid results. Thirty-six specimens were invalid on initial and repeat testing (as per the device's package insert) on the comparator device $( 3 . 2 \% )$ . The invalid specimens have been removed from the additional analysis. The Table 5.6 below details the results for the remaining 1072 specimens.

<table><tr><td rowspan=1 colspan=4>Table 5.6: Clinical Performance Data</td></tr><tr><td rowspan=1 colspan=1>Nasal/nasopharyngealswab (N=1072)</td><td rowspan=1 colspan=3>FDA Cleared RT-PCR</td></tr><tr><td rowspan=1 colspan=1>Quidel Molecular</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1007</td><td rowspan=1 colspan=1>1010</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>1009</td><td rowspan=1 colspan=1>1072</td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>60/63</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>86.7 to99.0%</td></tr><tr><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>1007/1009</td><td rowspan=1 colspan=1>99.8%</td><td rowspan=1 colspan=1>99.3% to100%</td></tr></table>

. \* Specimens negative for hMPV by sequence analysis

# Conclusions

Quidel Molecular hMPV Assay yielded good positive and negative percent agreement for nasal and nasopharyngeal swabs when compared to a 510(k) cleared molecular device.

Quidel Corporation   
c/o Ronald H. Lollar   
Senior Director, Clinical and Quality Affairs   
1055 East State Street   
Suite 100   
Athens, Ohio 45701

Re: K112490 Trade/Device Name: Quidel Molecular hMPV Assay Regulation Number: 21 CFR 866.3980 Regulation Name: Respiratory viral panel multiplex nucleic acid assay Regulatory Class: Class II Product Code: OEM Dated: November 18, 2011 Received: November 21, 2011

Dear Mr. Lollar:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976, the enactment date of the Medical Device Amendments, or to devices thal have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

Page 2 - Ronald H. Lollar

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will alow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed preicat evi reul n  classaton or your device nd thus, permts yourdevic proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/e1bb18868ddd21724ec8caf6025e5eb70a28b8be5a1f1219a98282f796c8b235.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use Statement

510(k) Number (if known): k112490

Device Name: Quidel Molecular hMPV Assay

# Indication for Use:

The Quidel Molecular hMPV assay is a multiplex Real Time RT-PCR assay for the in vitro qualitative detection of human metapneumovirus RNA in nasal and nasopharyngcal swab specimens from patients with signs and symptoms of respiratory infection. This test is intended for use as an aid in the differential diagnosis of human metapneumovirus infections in humans in conjunction with clinical and epidemiological risk factors. This test is not intended to differentiate the four genetic sub-lineages of hMPV.

Negative results do not preclude hMPV infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

Prescription Use Over-The-Counter Use X AND/OR (21 CFR 801 Subpart C) (Part 21 CFR 801 Subpart D)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

TamarJeldely Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(K) K112490